Primer Capital, a venture capital biotech fund, and Bayer have signed an agreement on the joint work to identify and develop the promising startups in the area of pharmaceuticals and biomedicine.
This collaboration will be implemented as part of Collaborator project on the basis of the biological faculty of M.V. Lomonosov Moscow State University. The project aims to support the research companies in the early stages of their development.
The agreement applies to the projects in such therapeutic areas, as oncology, cardiology, ophthalmology, and women’s health, that represent a priority for Bayer. Bayer will assess the projects in terms of their scientific prospects. It will advise the startups in the area of research and development, as well as on commercializing and bringing the innovative solutions to the market, while the Primer Capital will conduct a full-scale investment expert examination.
Elizaveta Rozhdestvenskaya, the Executive Director of Primer Capital, said, “This partnership will give us not only new access to the university R&D, but also an additional scientific filter represented by the experts of Bayer. Such extensive support for the projects will improve their preparation in order to seek further investments in the market.”
Niels Hessmann, the General Director of Bayer JSC, said, “The collaboration with Primer Capital allows the residents of Collaborator not only to convert their ideas into ready solutions and acquire strategic skills for commercializing the scientific results, but also to find financial support for their projects.”